ONC

SEC source: 0001651308-22-000144 · wf-form4_166008599777774.xml · nonDerivative · entry 24

Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F4 · security: Each American Depositary Share represents 13 Ordinary Shares.

F11 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 3, 2021, as most recently amended on June 15, 2022.

SEC source: 0001651308-22-000144 · wf-form4_166008599777774.xml · nonDerivative · entry 23

Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100

F4 · security: Each American Depositary Share represents 13 Ordinary Shares.

F11 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 3, 2021, as most recently amended on June 15, 2022.

SEC source: 0001651308-22-000144 · wf-form4_166008599777774.xml · nonDerivative · entry 22

Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 200

F4 · security: Each American Depositary Share represents 13 Ordinary Shares.

F11 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 3, 2021, as most recently amended on June 15, 2022.

F16 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $195.95 to $196.73, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

SEC source: 0001651308-22-000144 · wf-form4_166008599777774.xml · nonDerivative · entry 21

Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 800

F4 · security: Each American Depositary Share represents 13 Ordinary Shares.

F11 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 3, 2021, as most recently amended on June 15, 2022.

F15 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $194.80 to $195.79, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

SEC source: 0001651308-22-000144 · wf-form4_166008599777774.xml · nonDerivative · entry 20

Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,768

F4 · security: Each American Depositary Share represents 13 Ordinary Shares.

F11 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 3, 2021, as most recently amended on June 15, 2022.

F14 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $193.66 to $194.56, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

SEC source: 0001651308-22-000144 · wf-form4_166008599777774.xml · nonDerivative · entry 19

Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,412

F4 · security: Each American Depositary Share represents 13 Ordinary Shares.

F11 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 3, 2021, as most recently amended on June 15, 2022.

F13 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $192.62 to $193.60, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

SEC source: 0001651308-22-000144 · wf-form4_166008599777774.xml · nonDerivative · entry 18

Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,300

F4 · security: Each American Depositary Share represents 13 Ordinary Shares.

F11 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 3, 2021, as most recently amended on June 15, 2022.

SEC source: 0001651308-22-000144 · wf-form4_166008599777774.xml · nonDerivative · entry 17

Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,400

F4 · security: Each American Depositary Share represents 13 Ordinary Shares.

F11 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 3, 2021, as most recently amended on June 15, 2022.

SEC source: 0001651308-22-000144 · wf-form4_166008599777774.xml · nonDerivative · entry 16

Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,500

F4 · security: Each American Depositary Share represents 13 Ordinary Shares.

F11 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 3, 2021, as most recently amended on June 15, 2022.

SEC source: 0001651308-22-000144 · wf-form4_166008599777774.xml · nonDerivative · entry 15

Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,700

F4 · security: Each American Depositary Share represents 13 Ordinary Shares.

F11 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 3, 2021, as most recently amended on June 15, 2022.

F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $186.38 to $187.29, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

SEC source: 0001651308-22-000144 · wf-form4_166008599777774.xml · nonDerivative · entry 14

Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

F4 · security: Each American Depositary Share represents 13 Ordinary Shares.

F5 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2021, as most recently amended on June 15, 2022.

F2 · ownership.nature: These securities are held by Wang Investment LLC, of which 99% of the limited liability company interest is owned by two grantor retained annuity trusts, of which the Reporting Person's wife is a trustee, for which the Reporting Person disclaims beneficial ownership.

SEC source: 0001651308-22-000144 · wf-form4_166008599777774.xml · nonDerivative · entry 13

Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 100

F4 · security: Each American Depositary Share represents 13 Ordinary Shares.

F5 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2021, as most recently amended on June 15, 2022.

F2 · ownership.nature: These securities are held by Wang Investment LLC, of which 99% of the limited liability company interest is owned by two grantor retained annuity trusts, of which the Reporting Person's wife is a trustee, for which the Reporting Person disclaims beneficial ownership.

SEC source: 0001651308-22-000144 · wf-form4_166008599777774.xml · nonDerivative · entry 12

Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 200

F4 · security: Each American Depositary Share represents 13 Ordinary Shares.

F5 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2021, as most recently amended on June 15, 2022.

F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $196.45 to $196.72, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

F2 · ownership.nature: These securities are held by Wang Investment LLC, of which 99% of the limited liability company interest is owned by two grantor retained annuity trusts, of which the Reporting Person's wife is a trustee, for which the Reporting Person disclaims beneficial ownership.

SEC source: 0001651308-22-000144 · wf-form4_166008599777774.xml · nonDerivative · entry 11

Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 600

F4 · security: Each American Depositary Share represents 13 Ordinary Shares.

F5 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2021, as most recently amended on June 15, 2022.

F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $195.24 to $195.95, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

F2 · ownership.nature: These securities are held by Wang Investment LLC, of which 99% of the limited liability company interest is owned by two grantor retained annuity trusts, of which the Reporting Person's wife is a trustee, for which the Reporting Person disclaims beneficial ownership.

SEC source: 0001651308-22-000144 · wf-form4_166008599777774.xml · nonDerivative · entry 10

Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 1,600

F4 · security: Each American Depositary Share represents 13 Ordinary Shares.

F5 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2021, as most recently amended on June 15, 2022.

F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $194.21 to $194.70, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

F2 · ownership.nature: These securities are held by Wang Investment LLC, of which 99% of the limited liability company interest is owned by two grantor retained annuity trusts, of which the Reporting Person's wife is a trustee, for which the Reporting Person disclaims beneficial ownership.

SEC source: 0001651308-22-000144 · wf-form4_166008599777774.xml · nonDerivative · entry 9

Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 2,200

F4 · security: Each American Depositary Share represents 13 Ordinary Shares.

F5 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2021, as most recently amended on June 15, 2022.

F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $193.19 to $194.17, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

F2 · ownership.nature: These securities are held by Wang Investment LLC, of which 99% of the limited liability company interest is owned by two grantor retained annuity trusts, of which the Reporting Person's wife is a trustee, for which the Reporting Person disclaims beneficial ownership.

SEC source: 0001651308-22-000144 · wf-form4_166008599777774.xml · nonDerivative · entry 8

Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 4,300

F4 · security: Each American Depositary Share represents 13 Ordinary Shares.

F5 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2021, as most recently amended on June 15, 2022.

F2 · ownership.nature: These securities are held by Wang Investment LLC, of which 99% of the limited liability company interest is owned by two grantor retained annuity trusts, of which the Reporting Person's wife is a trustee, for which the Reporting Person disclaims beneficial ownership.

SEC source: 0001651308-22-000144 · wf-form4_166008599777774.xml · nonDerivative · entry 7

Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 4,400

F4 · security: Each American Depositary Share represents 13 Ordinary Shares.

F5 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2021, as most recently amended on June 15, 2022.

F2 · ownership.nature: These securities are held by Wang Investment LLC, of which 99% of the limited liability company interest is owned by two grantor retained annuity trusts, of which the Reporting Person's wife is a trustee, for which the Reporting Person disclaims beneficial ownership.

SEC source: 0001651308-22-000144 · wf-form4_166008599777774.xml · nonDerivative · entry 6

Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 4,500

F4 · security: Each American Depositary Share represents 13 Ordinary Shares.

F5 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2021, as most recently amended on June 15, 2022.

F2 · ownership.nature: These securities are held by Wang Investment LLC, of which 99% of the limited liability company interest is owned by two grantor retained annuity trusts, of which the Reporting Person's wife is a trustee, for which the Reporting Person disclaims beneficial ownership.

SEC source: 0001651308-22-000144 · wf-form4_166008599777774.xml · nonDerivative · entry 5

Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 4,700

F4 · security: Each American Depositary Share represents 13 Ordinary Shares.

F5 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2021, as most recently amended on June 15, 2022.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $186.38 to $187.32, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

F2 · ownership.nature: These securities are held by Wang Investment LLC, of which 99% of the limited liability company interest is owned by two grantor retained annuity trusts, of which the Reporting Person's wife is a trustee, for which the Reporting Person disclaims beneficial ownership.

SEC source: 0001651308-22-000119 · wf-form4_165705652132138.xml · nonDerivative · entry 2

Wang Julia Aijun · CIK 0001860279 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F2 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 30, 2020, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.

SEC source: 0001651308-22-000125 · wf-form4a_165817931742680.xml · nonDerivative · entry 2

Wang Julia Aijun · CIK 0001860279 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F2 · security: Each American Depositary Share represents 13 Ordinary Shares.

F3 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 30, 2020, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.

F1 · shares: The original Form 4, filed on July 5, 2022, is being amended by this Form 4 amendment solely to correct an administrative error, which misreported a sale that occurred on July 1, 2022 as a total of 295 American Depositary Shares ("ADSs") sold when in fact 317 ADSs were sold. As a result of this administrative error, the number of Ordinary Shares beneficially owned by the reporting person following the corrected transaction reflects a reduction in the number of Ordinary Shares reported as beneficially owned by the reporting person by 286 Ordinary Shares.

SEC source: 0001651308-22-000115 · wf-form4_165645195007556.xml · nonDerivative · entry 4

Wang Lai · CIK 0001852291 · Global Head of R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F5 · security: Each American Depositary Share represents 13 Ordinary Shares.

F6 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 26, 2018, subject to continued service.

SEC source: 0001651308-22-000114 · wf-form4_165610682207683.xml · derivative · entry 7

OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,887,678

Underlying: Ordinary Shares · 1,887,678 shares

Expires 2032-06-21

F7 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares.

F7 · shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares.

F8 · derivative.exercise_date: These securities vest over a four-year period as follows: 25% on the first anniversary of June 22, 2022 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested shares are subject to accelerated vesting upon change of control or certain termination events.

SEC source: 0001651308-22-000114 · wf-form4_165610682207683.xml · nonDerivative · entry 1

OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,070,913

F1 · security: Represents securities underlying restricted share units. 1/4th of the securities will vest on each anniversary of June 22, 2022, subject to continued service. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events.

SEC source: 0001209191-22-039274 · doc4.xml · derivative · entry 9

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 69,290

Underlying: Ordinary Shares · 69,290 shares

Expires 2032-06-21

F14 · derivative.exercise_date: 34,645 Share Options each granted to Michael Goller and Ranjeev Krishana, full-time employees of the Adviser, in their capacity as directors of the Issuer under the 2016 Plan. The Share Options have a strike price of $11.98 and vest upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting of the Issuer, provided, however, that all vesting shall cease if Michael Goller or Ranjeev Krishana resigns from the Board or otherwise ceases to serve as a director, unless the Board determines otherwise.

F1 · ownership.nature: American Depositary Shares ("ADS") of BeiGene, Ltd. (the "Issuer") each represent 13 Ordinary Shares ("Ordinary Shares") of the Issuer.

F5 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to 667 and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds"). In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds.

F6 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

F11 · ownership.nature: Pursuant to the policies of the Adviser, Michael Goller and Ranjeev Krishana do not have any right to any of the Issuer's securities issued as part of their service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in the securities. The Funds each own an indirect proportionate pecuniary interest in the Ordinary Shares received upon vesting of RSUs and non-qualified share options convertible solely into Ordinary Shares of the Issuer ("Share Options") received as a result of their service on the Board. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the Ordinary Shares received upon vesting of RSUs, Share Options, and Ordinary Shares received upon the exercise of Share Options (i.e. no direct pecuniary interest).

F12 · ownership.nature: The Adviser has voting and dispositive power over the Share Options, RSUs and any Ordinary Shares received as a result of the exercise of Share Options or vesting of RSUs.

F14 · ownership.nature: 34,645 Share Options each granted to Michael Goller and Ranjeev Krishana, full-time employees of the Adviser, in their capacity as directors of the Issuer under the 2016 Plan. The Share Options have a strike price of $11.98 and vest upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting of the Issuer, provided, however, that all vesting shall cease if Michael Goller or Ranjeev Krishana resigns from the Board or otherwise ceases to serve as a director, unless the Board determines otherwise.

F15 · ownership.nature: The Share Options expire on June 21, 2032. Michael Goller and Ranjeev Krishana serve on the Board of the Issuer as representatives of the Funds. Unvested Share Options are subject to accelerated vesting upon a change in control and certain termination events.

SEC source: 0001209191-22-039274 · doc4.xml · nonDerivative · entry 8

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 67,573

F1 · ownership.nature: American Depositary Shares ("ADS") of BeiGene, Ltd. (the "Issuer") each represent 13 Ordinary Shares ("Ordinary Shares") of the Issuer.

F5 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to 667 and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds"). In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds.

F6 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

F7 · ownership.nature: After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker may be deemed to have an indirect pecuniary interest in Ordinary Shares or ADS, as applicable, reported in column 5 of Table I directly held by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.

F10 · ownership.nature: Includes beneficial ownership of 17,082 Ordinary Shares received from vested restricted share units convertible solely into Ordinary Shares of the Issuer ("RSUs") each previously granted to Michael Goller and Ranjeev Krishana, full-time employees of the Adviser, in their capacity as directors of the Issuer. Michael Goller and Ranjeev Krishana serve on the board of directors of the Issuer (the "Board") as representatives of the Funds.

F11 · ownership.nature: Pursuant to the policies of the Adviser, Michael Goller and Ranjeev Krishana do not have any right to any of the Issuer's securities issued as part of their service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in the securities. The Funds each own an indirect proportionate pecuniary interest in the Ordinary Shares received upon vesting of RSUs and non-qualified share options convertible solely into Ordinary Shares of the Issuer ("Share Options") received as a result of their service on the Board. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the Ordinary Shares received upon vesting of RSUs, Share Options, and Ordinary Shares received upon the exercise of Share Options (i.e. no direct pecuniary interest).

F12 · ownership.nature: The Adviser has voting and dispositive power over the Share Options, RSUs and any Ordinary Shares received as a result of the exercise of Share Options or vesting of RSUs.

F13 · ownership.nature: 16,692 RSUs granted to each of Michael Goller and Ranjeev Krishana on June 22, 2022, pursuant to the Issuer's 2016 Share Option and Incentive Plan (the "2016 Plan"). The RSUs vest upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting of the Issuer, provided, however, that all vesting shall cease if Michael Goller or Ranjeev Krishana resigns from the Board or otherwise ceases to serve as a director, unless the Board determines otherwise.

F14 · ownership.nature: 34,645 Share Options each granted to Michael Goller and Ranjeev Krishana, full-time employees of the Adviser, in their capacity as directors of the Issuer under the 2016 Plan. The Share Options have a strike price of $11.98 and vest upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting of the Issuer, provided, however, that all vesting shall cease if Michael Goller or Ranjeev Krishana resigns from the Board or otherwise ceases to serve as a director, unless the Board determines otherwise.

SEC source: 0001209191-22-039274 · doc4.xml · nonDerivative · entry 7

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 67,569

F1 · ownership.nature: American Depositary Shares ("ADS") of BeiGene, Ltd. (the "Issuer") each represent 13 Ordinary Shares ("Ordinary Shares") of the Issuer.

F4 · ownership.nature: After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, L.P. ("667"), Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Ordinary Shares or ADS, as applicable, reported in column 5 of Table I directly held by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.

F5 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to 667 and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds"). In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds.

F6 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

F10 · ownership.nature: Includes beneficial ownership of 17,082 Ordinary Shares received from vested restricted share units convertible solely into Ordinary Shares of the Issuer ("RSUs") each previously granted to Michael Goller and Ranjeev Krishana, full-time employees of the Adviser, in their capacity as directors of the Issuer. Michael Goller and Ranjeev Krishana serve on the board of directors of the Issuer (the "Board") as representatives of the Funds.

F11 · ownership.nature: Pursuant to the policies of the Adviser, Michael Goller and Ranjeev Krishana do not have any right to any of the Issuer's securities issued as part of their service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in the securities. The Funds each own an indirect proportionate pecuniary interest in the Ordinary Shares received upon vesting of RSUs and non-qualified share options convertible solely into Ordinary Shares of the Issuer ("Share Options") received as a result of their service on the Board. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the Ordinary Shares received upon vesting of RSUs, Share Options, and Ordinary Shares received upon the exercise of Share Options (i.e. no direct pecuniary interest).

F12 · ownership.nature: The Adviser has voting and dispositive power over the Share Options, RSUs and any Ordinary Shares received as a result of the exercise of Share Options or vesting of RSUs.

F13 · ownership.nature: 16,692 RSUs granted to each of Michael Goller and Ranjeev Krishana on June 22, 2022, pursuant to the Issuer's 2016 Share Option and Incentive Plan (the "2016 Plan"). The RSUs vest upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting of the Issuer, provided, however, that all vesting shall cease if Michael Goller or Ranjeev Krishana resigns from the Board or otherwise ceases to serve as a director, unless the Board determines otherwise.

SEC source: 0001651308-22-000112 · wf-form4_165610678473488.xml · derivative · entry 2

Wang Julia Aijun · CIK 0001860279 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 589,888

Underlying: Ordinary Shares · 589,888 shares

Expires 2032-06-21

F2 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares.

F2 · shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares.

F3 · derivative.exercise_date: These securities vest over a four-year period as follows: 25% on the first anniversary of June 22, 2022 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events following a change in control.

SEC source: 0001651308-22-000112 · wf-form4_165610678473488.xml · nonDerivative · entry 1

Wang Julia Aijun · CIK 0001860279 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 245,583

F1 · security: Represents securities underlying restricted share units. 1/4th of the securities will vest on each anniversary of June 22, 2022, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events following a change in control.

SEC source: 0001651308-22-000113 · wf-form4_165610680385112.xml · derivative · entry 4

Wang Lai · CIK 0001852291 · Global Head of R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 707,876

Underlying: Ordinary Shares · 707,876 shares

Expires 2032-06-21

F6 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares.

F6 · shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares.

F7 · derivative.exercise_date: These securities vest over a four-year period as follows: 25% on the first anniversary of June 22, 2022 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service.

SEC source: 0001651308-22-000113 · wf-form4_165610680385112.xml · nonDerivative · entry 1

Wang Lai · CIK 0001852291 · Global Head of R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,509,989

F1 · security: Represents securities underlying restricted share units. 1/4th of the securities will vest on each anniversary of June 22, 2022, subject to continued service.

SEC source: 0001651308-22-000104 · wf-form4_165610662726306.xml · derivative · entry 3

Malley Thomas · CIK 0001403322 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,645

Underlying: Ordinary Shares · 34,645 shares

Expires 2032-06-21

F3 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares.

F3 · shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares.

F4 · derivative.exercise_date: The option shall become exercisable in full upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. The option was granted under the Company's Independent Director Compensation Policy, as amended.

SEC source: 0001651308-22-000104 · wf-form4_165610662726306.xml · nonDerivative · entry 1

Malley Thomas · CIK 0001403322 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,774

F1 · security: Represents securities underlying restricted share units. The restricted share units shall become fully vested on the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the director resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. The restricted share unites were granted under the Company's Independent Director Compensation Policy, as amended.

SEC source: 0001651308-22-000108 · wf-form4_165610670088035.xml · derivative · entry 2

HOOPER ANTHONY C · CIK 0001277244 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,645

Underlying: Ordinary Shares · 34,645 shares

Expires 2032-06-21

F2 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 Ordinary Shares.

F2 · shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 Ordinary Shares.

F3 · derivative.exercise_date: The option shall become exercisable in full upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. The option was granted under the Company's Independent Director Compensation Policy, as amended.

SEC source: 0001651308-22-000108 · wf-form4_165610670088035.xml · nonDerivative · entry 1

HOOPER ANTHONY C · CIK 0001277244 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,492

F1 · security: Represents securities underlying restricted share units. The restricted share units shall become fully vested on the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the director resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. The restricted share unites were granted under the Company's Independent Director Compensation Policy, as amended.

SEC source: 0001651308-22-000111 · wf-form4_165610676599580.xml · derivative · entry 5

Wu Xiaobin · CIK 0001739452 · President, COO & GM China

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,061,814

Underlying: Ordinary Shares · 1,061,814 shares

Expires 2032-06-21

F6 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares.

F6 · shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares.

F7 · derivative.exercise_date: These securities vest over a four-year period as follows: 25% on the first anniversary of June 22, 2022, and the remaining in 36 successive equal monthly installments, subject to continued service. Unvested shares are subject to accelerated vesting upon certain termination events following a change in control.

SEC source: 0001651308-22-000111 · wf-form4_165610676599580.xml · nonDerivative · entry 1

Wu Xiaobin · CIK 0001739452 · President, COO & GM China

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 987,867

F1 · security: Represents securities underlying restricted share units. 1/4th of the securities will vest on each anniversary of June 22, 2022, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events following a change in control.

SEC source: 0001651308-22-000110 · wf-form4_165610674812871.xml · derivative · entry 2

Dugan Margaret · CIK 0001909734 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,645

Underlying: Ordinary Shares · 34,645 shares

Expires 2032-06-21

F2 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares.

F2 · shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares.

F3 · derivative.exercise_date: The option shall become exercisable in full upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. The option was granted under the Company's Independent Director Compensation Policy, as amended.

SEC source: 0001651308-22-000110 · wf-form4_165610674812871.xml · nonDerivative · entry 1

Dugan Margaret · CIK 0001909734 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,692

F1 · security: Represents securities underlying restricted share units. The restricted share units shall become fully vested on the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the director resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. The restricted share unites were granted under the Company's Independent Director Compensation Policy, as amended.

SEC source: 0001651308-22-000109 · wf-form4_165610672523116.xml · derivative · entry 6

Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 471,913

Underlying: Ordinary Shares · 471,913 shares

Expires 2032-06-21

F6 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares.

F6 · shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares.

F7 · derivative.exercise_date: These securities vest over a four-year period as follows: 25% on the first anniversary of June 22, 2022 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service.

SEC source: 0001651308-22-000109 · wf-form4_165610672523116.xml · nonDerivative · entry 1

Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,806,746

F1 · security: Represents securities underlying restricted share units. 1/4th of the securities will vest on each anniversary of June 22, 2022, subject to continued service.

SEC source: 0001651308-22-000107 · wf-form4_165610668501437.xml · derivative · entry 2

Glazer Donald W. · CIK 0001660940 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,645

Underlying: Ordinary Shares · 34,645 shares

Expires 2032-06-21

F2 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 Ordinary Shares.

F2 · shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 Ordinary Shares.

F3 · derivative.exercise_date: The option shall become exercisable in full upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. The option was granted under the Company's Independent Director Compensation Policy, as amended.

SEC source: 0001651308-22-000107 · wf-form4_165610668501437.xml · nonDerivative · entry 1

Glazer Donald W. · CIK 0001660940 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,771,221

F1 · security: Represents securities underlying restricted share units. The restricted share units shall become fully vested on the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the director resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. The restricted share unites were granted under the Company's Independent Director Compensation Policy, as amended.

SEC source: 0001651308-22-000106 · wf-form4_165610666171630.xml · derivative · entry 2

Riva Alessandro · CIK 0001867172 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,645

Underlying: Ordinary Shares · 34,645 shares

Expires 2032-06-21

F2 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares.

F2 · shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares.

F3 · derivative.exercise_date: The option shall become exercisable in full upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. The option was granted under the Company's Independent Director Compensation Policy, as amended.

SEC source: 0001651308-22-000106 · wf-form4_165610666171630.xml · nonDerivative · entry 1

Riva Alessandro · CIK 0001867172 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,692

F1 · security: Represents securities underlying restricted share units. The restricted share units shall become fully vested on the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the director resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. The restricted share unites were granted under the Company's Independent Director Compensation Policy, as amended.

SEC source: 0001651308-22-000105 · wf-form4_165610664484850.xml · derivative · entry 2

Sanders Corazon (Corsee) D. · CIK 0001796536 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,645

Underlying: Ordinary Shares · 34,645 shares

Expires 2032-06-21

F2 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 Ordinary Shares.

F2 · shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 Ordinary Shares.

F3 · derivative.exercise_date: The option shall become exercisable in full upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. The option was granted under the Company's Independent Director Compensation Policy, as amended.

SEC source: 0001651308-22-000105 · wf-form4_165610664484850.xml · nonDerivative · entry 1

Sanders Corazon (Corsee) D. · CIK 0001796536 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,492

F1 · security: Represents securities underlying restricted share units. The restricted share units shall become fully vested on the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the director resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. The restricted share unites were granted under the Company's Independent Director Compensation Policy, as amended.

SEC source: 0000902664-22-003398 · ownership.xml · derivative · entry 2

Yi Qingqing · CIK 0001662556 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,645

Underlying: Ordinary Shares · 34,645 shares

Expires 2032-06-21

F2 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each ADS represents 13 ordinary shares.

F2 · shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each ADS represents 13 ordinary shares.

F3 · derivative.exercise_date: The option shall become exercisable in full upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events.

SEC source: 0000902664-22-003398 · ownership.xml · nonDerivative · entry 1

Yi Qingqing · CIK 0001662556 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,492

F1 · security: Represents securities underlying RSUs. All RSUs will vest upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events.